CYP19A1 and osteoporosis: For osteoporosis preventive care, the BMD test utilization rate among aromatase inhibitors recipients adhered to guidelines, faring better than an Israeli cohort of comparable age where a smaller proportion of survivors with at least one test was observed (73.5% v 92.2%).27 Complemented with high coverage of nutritional supplementation, practitioners demonstrated high awareness of this high-risk group.